Trial Profile

A Phase 1, Open-Label, Dose Escalation Study of ASG-5ME in Patients With Pancreatic or Gastric Adenocarcinoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ASG 5ME (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Pancreatic cancer; Pancreatic ductal carcinoma
Focus Adverse reactions; First in man
Sponsors Seagen

Most Recent Events

18 Mar 2016 Results published in the Investigational New Drugs
07 May 2013 Status changed from recruiting to active, no longer recruiting, according to a Seattle Genetics media release.
25 Jan 2013 Enrollment of patients with pancreatic ductal adenocarcinoma has been completed according to a Seattle Genetics media release. Enrollment of patients with relapsed/refractory gastric adenocarcinoma is ongoing.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com